Pronostic Factors in Elderly Patients Admitted to the Intensive Care Unit for Aneurysmal Subarachnoid Hemorrhage (FAPPAR-HSA)

March 31, 2026 updated by: ALB Ionel mircea, Central Hospital, Nancy, France

Pronostic Factors in Elderly Patients Admitted to the Intensive Care Unit for Aneurysmal Subarachnoid Hemorrhage Multicenter Retrospective Observational Study FAPPAR-HSA

Subarachnoid hemorrhage (SAH) represents a significant proportion of hemorrhagic strokes. Severe SAH in elderly patients is associated with poorer outcomes compared to younger cohorts. Better characterization of both short- and long -term prognosis in these patients is necessary to facilitate medical decision-making in the intensive care unit (ICU)

Primary Objective:

The primary objective is to identify prognostic factors associated with poor functional outcome or death at 6 months (± 2 months) in elderly patients admitted to the ICU for SAH.

Secondary Objectives:

To evaluate in-hospital mortality among elderly patients admitted to the ICU for SAH.

To describe the causes of in-hospital death (brain death, withholding/withdrawal of life-sustaining treatment [WOLST], other medico-surgical causes) in elderly patients admitted to the ICU for SAH.

To describe the care trajectory following hospital discharge for elderly patients admitted to the ICU for SAH.

To evaluate the mean length of stay in the ICU and in the hospital (acute care) for elderly patients admitted to the ICU for SAH.

To identify prognostic factors associated with poor functional outcome or death at 1 year in elderly patients admitted to the ICU for SAH.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

170

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ionel M ALB, MD Intensive Care/Anesthesia
  • Phone Number: 0033-661028367
  • Email: im.alb@chru-nancy.fr

Study Locations

  • France
      • Nancy, France, 54000
        • CHRU Nancy
        • Contact:
        • Principal Investigator:
          • Ionel M ALB, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adult patients admitted in ICU for aneurysmal subarachnoid hemorrhage in 4 University Hospital Centers in France (CHU Nancy, CHU Reims, HC de Lyon, CHU Lille) between Juin 30, 2021 et Juin 30, 2025

Description

Inclusion Criteria:

  • Patients hospitalized in ICU for aneurysmal subarachnoid hemorrhage
  • Aged 70 years or over the day of admission in ICU
  • Between Juin 30, 2021 and Juin 30, 2025

Exclusion Criteria:

  • Decline to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Elderly aneurysmal SAH patients hospitalized in ICU
Patients hospitalized in ICU for aneurysmal subarachnoid hemorrhage between Juin 30, 2021 and Juin 30, 2025. Aged 70 years or over the day of admission in ICU. In accordance with French regulations , the study included patients who did not object to the use of their clinical data after receiving written information.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Rankin Scale (MRS) et 6 months
Time Frame: 6 months after ICU discharge
MRS : scale from 1(no symptoms) to 6 (dead) Good outcome : 0 - 2 Bad outcome: 3 - 6 The MRS grade is either collected if already available in the medical file or estimated retrospectively based on the patient neurological evaluation.
6 months after ICU discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intrahospital mortality
Time Frame: Day 28
Intrahospital mortality = percentage of deaths occuring during the initial hospitalisation (in the ICU and the neurosurgical/neurological ward)
Day 28
Cause of intrahospital death
Time Frame: Day 28
Percentage of the following categories: cerebral death, WOLST, surgical causes and medical causes
Day 28
Destination upon hospital discharge
Time Frame: Day 28
Percentage of the following categories: Discharge to Home versus Rehabilitation Unit versus Another Inpatient Ward (non-neurosurgical)
Day 28
Modified Rankin Scale upon discharge from hospital.
Time Frame: Day 28
MRS retrieved or estimated from patient's file data at the moment of ICU or neurosurgical ward discharge.
Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Investigators

  • Study Chair: Viviane MARTIN, Chief of Research Departement, CHRU NANCY, DRCI
  • Study Chair: Elodie JEANBERT, Methodologist, Statistician, CHRU NANCY, DRCI

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

March 16, 2026

First Submitted That Met QC Criteria

March 31, 2026

First Posted (Actual)

April 2, 2026

Study Record Updates

Last Update Posted (Actual)

April 2, 2026

Last Update Submitted That Met QC Criteria

March 31, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025PI114

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Subarachnoid Hemorrhage, Aneurysmal

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe